
A Multi-center, Open-label Study of Oral ENMD-2076 for the Treatment of Patients With Advanced Fibrolamellar...
Advanced Adult Hepatocellular CarcinomaAdvanced Fibrolamellar CarcinomaThe purpose of the study is to determine whether once-daily dosing with ENMD-2076 will be a safe and effective treatment in patients with FLC. Safety will be measured by looking at the adverse events that may happen and the efficacy will look at the progression of the disease over time.

Metformin and Omega-3 Fatty Acids in Woman With a History of Early Stage Breast Cancer
Stage 0 Breast CarcinomaBreast Neoplasms3 moreThe purpose of this study is to determine whether it is feasible to give a combination of Metformin and omega-3 fatty acids for one year to women with a history of early stage breast cancer. We will also evaluate whether the metformin and omega-3 fatty acids combination causes changes in breast tissue, blood, and mammograms.

Enzalutamide in Combination With Gemcitabine and Cisplatin in Bladder Cancer
Bladder CancerCarcinoma4 moreThe main purpose of this study is to find out the dose of enzalutamide that can be safely given with gemcitabine and cisplatin in patients with advanced bladder cancer. Researchers also want to find out the side effects of these drugs when given together. This study will also help in finding out the effect on tumor of the combination of enzalutamide, gemcitabine and cisplatin.

One-stop-shop Study for Treatment of Basal Cell Carcinoma Using Reflectance Confocal Microscopy...
CarcinomaBasal CellThe purpose of this study is to assess the efficacy and safety of the one-stop-shop concept, using real-time in vivo reflectance confocal microscopy as diagnostic tool, prior to surgical management of new primary basal cell carcinoma

Treating Peritoneal Carcinomatosis With PIPAC
Peritoneal CarcinomatosisThis is a feasibility study that aims to evaluate whether PIPAC (Pressurized Intraperitoneal Aerosol Chemotherapy) is a safe and feasible treatment in Danish patients with peritoneal cancer.

A Phase I Evaluating Integration of HypofractionatedStudy Renal Ablative Radiotherapy
Renal Cell Carcinomaevaluate the safety and toxicity profile of renal radio-ablation in the setting of metastatic renal cell carcinoma. to assess renal function post radio-ablation Primary and metastatic tumour response to radio-ablation

Study of ONT-10 and Varlilumab to Treat Advanced Ovarian or Breast Cancer
Advanced Breast CarcinomaAdvanced Ovarian CarcinomaThis is a two-part Phase 1b, open-label study of ONT 10 administered in combination with varlilumab. Two different doses of varlilumab will be studied in combination with the single agent recommended dose of ONT 10. Intermediate and/or lower doses of varlilumab or ONT-10 may also be studied at the recommendation of the safety monitoring committee (SMC).

Nintedanib and Capecitabine in Treating Patients With Refractory Metastatic Colorectal Cancer
Colon AdenocarcinomaRectal Adenocarcinoma6 moreThis phase I/II trial studies the side effects and best dose of nintedanib when given together with capecitabine and to see how well they work in treating patients with colorectal cancer that has not responded to previous treatment (refractory) and has spread to other places in the body (metastatic). Nintedanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It may also block the growth of new blood vessels necessary for tumor growth. Drugs used in chemotherapy, such as capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving nintedanib with capecitabine may be a better treatment for colorectal cancer.

Phase I Trial Of IMRT Using A Contralateral Esophagus Sparing Technique (CEST) In Locally Advanced...
Non-small Cell Lung CarcinomaSmall Cell Lung CarcinomaThis research study is examining the benefit of a novel radiation planning approach on the likelihood of developing severe esophagitis (irritation and inflammation of the esophagus) during the course of radiation therapy with concurrent chemotherapy which is associated with very painful and difficult swallowing.

Trial of TRC105 and Sorafenib in Patients With HCC
Hepatocellular CarcinomaThe purpose of the phase 1b portion is to evaluate safety and tolerability and determine a recommended phase 2 dose for TRC105 when added to standard dose sorafenib in patients with hepatocellular carcinoma. Up to 18 patients will be treated. The purpose of the phase 2 portion is to estimate the ORR of patients with hepatocellular carcinoma by RECIST 1.1. Up to 21 patients will be treated in phase 2.